Long-term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alfa

Hepatology

Volumn 26, Issue 5, 1997, Pages 1338-1342

  Fattovich, Giovanna ^a   Giustina, Giuliano ^b   Realdi, Giuseppe ^c   Corrocher, Roberto ^a   Schalm, Solko W ^d  

^a UNIVERSITY OF VERONA   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c UNIVERSITY OF SASSARI   (Italy)

^d ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; HEPATITIS B(E) ANTIGEN;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; HEPATITIS B; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REMISSION; SURVIVAL;

EID: 0030696048     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.510260536     Document Type: Article

References (15)

1. Fattovich G. Natural course and prognosis of chronic hepatitis type B. Viral Hep Rev 1996;2:263-276.
2. Korenman J, Baker B, Waggoner J, Everhart JE, Di Bisceglie AM, Hoofnagle JH. Long-term remission of chronic hepatitis B after alpha-interferon therapy. Ann Intern Med 1991; 114:629-634.
3. Wong DKH, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med 1993;119:312-323.
4. Hoofnagle JH, Di Bisceglie AM. The treatment of chronic viral hepatitis. N Engl J Med 1997;336:347-356.
5. Niederau C, Heintges T, Lange S, Goldmann G, Niederau CM, Mohr L, Haussinger D. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996; 334:1422-1427.
6. Realdi G, Fattovich G, Hadziyannis S, Schalm SW, Almasio P, Sanchez-Tapias J, Christensen E, et al. Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a multicenter study. J Hepatol 1994;21:656-666.
7. Fattovich G, Giustina G, Schalm SW, Hadziyannis S, Sanchez-Tapias J, Almasio P, Christensen E, et al. Occurrence of hepatocellular carcinoma and decompensation in Western European patients with cirrhosis type B. HEPATOLOGY 1995;21:77-82.
8. Sackett DL, Haynes RB, Guyatt GH, Tugwell P. Clinical epidemiology. A basic science for clinical medicine. Boston: Little, Brown and Company, 1991.
9. Infante-Rivard C, Villeneuve JP, Esnaola S. A framework for evaluating and conducting prognostic studies: an application to cirrhosis of the liver. J Clin Epidemiol 1989;42:791-805.
10. Bianchi L, De Groote J, Desmet VJ, Gedik P, Korb G, Popper H, Poulsen H, et al. Acute and chronic hepatitis revisited. Lancet 1977;2:914-919.
11. Kaplan EL, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc 1958;53:457-481.
12. Peto R, Pike MC. Conservatism of the approximation (0-E)/E in the logrank test for survival data on tumor incidence data. Biometrics 1973; 29:579-584.
13. Cox DR. Regression models and life tables [with discussion]. J R Stat Soc B 1972;34:187-220.
14. Krogsgaard K, Christensen E, Bindslev N, Schalm S, Andersen PK, Ring-Larsen H, and the European Concerted Action on Viral Hepatitis (Eurohep). Relation between treatment efficacy and cumulative dose of alpha Interferon in chronic hepatitis B. J Hepatol 1996;25:795-802.
15. Popper H, Shafritz DA, Hoofnagle JH. Relation of the hepatitis B virus carrier state to hepatocellular carcinoma. HEPATOLOGY 1987;7:764-772.